Company Profile

Innovacell Biotechnologie AG is the first company to have developed a personalized, cell-based therapy for the treatment of stress urinary incontinence (SUI). Innovacell’s lead product ICES13, is set out to receive regulatory approval by EMA in 2013. As of today, four European authorities have approved Innovacell’s clinical trial program. Patients are enrolling to be treated at more than 40 centres, including centres in Germany and elsewhere across Europe.

Innovacell’s multinational Phase IIb clinical trial builds on broad experience. More than 500 SUI patients were treated prior to the entry into force of EU guideline 1394/2007 on December 2008. Innovacell has successfully completed Phase I/II trials.

Innovacell’s other cell-based therapy, ICEF15, is for the treatment of faecal incontinence, for which there is a particularly high medical need. Following the successful completion of Phase I/II trials, Innovacell is planning to start multicentre clinical trials for ICEF15 in 2011.

Unlike any other medical product for incontinence, Innovacell’s cell therapies offer a natural, minimally invasive, and potentially one-time, lifelong cure. Innovacell’s cell therapy has the potential to set a new standard in the treatment of SUI and faecal incontinence.

Innovacell Biotechnologie AG is privately-owned and based in Innsbruck, Austria.